BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  ProQR Candidate for Inherited Retinal Disorder Misses in Phase III

  ProQR Therapeutics has reported that their drug sepofarsen failed to meet its primary and secondary endpoints in recent Phase II/III clinical trials.

  February 14, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Business

  East Coast Pain Player Expands Portfolio with $604M Buyout

  Stoughton, Mass.-based Collegium Pharmaceutical is expanding its pain-treating portfolio with a $604 million buyout of Raleigh’s BioDelivery Sciences International (BDSI).

  February 14, 2022

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Drug Development

  Lilly, Roche Push Back Against CMS Draft Guidance on Aduhelm

  CMS says it would only cover the cost of Biogen’s Aduhelm and any required scans “if they are enrolled in qualifying clinical trials.”

  February 14, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Chameleon’s Cloaking Technology Makes Multi-Dose Gene Therapy a Reality

  With EVADER, the Chameleon team hopes to make one-and-done treatments a relic of the past.

  February 14, 2022

   · 

  5 min read

   · 

  Abbey Glasure
• 

  Business

  UK and Moderna Appear to Be Heading for Manufacturing Altar

  Moderna is reportedly in talks with the UK government to establish mRNA manufacturing facilities in the country, as well as collaborating with health authorities on clinical trials.

  February 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Career Advice

  The Most In-Demand Pharma Qualifications

  Discover the most in-demand pharma qualifications and how to use them to score your dream job in our comprehensive guide.

  February 14, 2022

   · 

  5 min read

   · 

  Franklin Carpenter
• 

  Drug Development

  REGENXBIO’s Week of Gene Therapy Successes in Diabetic Retinopathy and MPS

  Six months after the one-time treatment, 47% of patients in Cohort 1 demonstrated a promising two-step or greater improvement in their diabetic retinopathy.

  February 14, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Lilly’s New Weapon Against Omicron Approved with Orders Aplenty

  Eli Lilly’s proposed antibody drug bebtelovimab has received EUA from the FDA after demonstrating its potency against SARS-CoV-2’s Omicron variant.

  February 14, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Roivant Aims New “Vant” at Anemia Space Dominated by BMS

  Roivant Sciences launches new subsidiary Hemavant that will develop Eisai-licensed asset for transfusion-dependent anemia in patients with low-risk MDS.

  February 14, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  WHO Tracking 4 Omicron Subvariants while a New Antibody Gets the Nod

  Although the Omicron surge appears to be waning in the U.S., the World Health Organization keeps an eye on four Omicron subvariants.

  February 14, 2022

   · 

  5 min read

   · 

  Mark Terry